Biopreservation and Biobanking最新文献

Introduction: This study is part of the broader Stem Line project Mito-Cell-UAB073, specifically focusing on "Stem Cell Lines-Quality Control," and aims to innovate in the field of Quality Control (QC) through a unique, artificial intelligence (AI)-powered model known as Life Cell AI UAB. This model utilizes deep learning algorithms and computer vision, allowing it to make accurate viability assessments of cell and stem cell lines based solely on static images captured through standard optical microscopes. Aim: The aim of this study was to develop and validate an AI-driven, image-based model that reliably predicts cell line viability. Methods: Our methodology involved training the Life Cell AI UAB model on single static images of cell lines using advanced computer vision and deep learning techniques. Performance evaluation was conducted on three independent blind test sets sourced from various biotechnology laboratories, allowing for assessment across diverse environments. Results: The Life Cell AI UAB model achieved a sensitivity of 82.1% in identifying viable cell lines and a specificity of 67.5% for non-viable lines across the test sets. Each blind test set exhibited a weighted accuracy above 63%, with a combined accuracy of 64.3%. Notably, predictions showed a clear distinction between correctly and incorrectly classified cells. The model outperformed traditional QC methods by improving accuracy in binary classification tasks by 21.9% (p = 0.042) and demonstrated a 42.0% enhancement over conventional Standard Operation Procedure (SOP) procedures (p = 0.026). Conclusion: The Life Cell AI UAB model represents a notable advancement in biobanking QC, offering a precise, standardized, and non-invasive method for assessing cell line viability. This model has the potential to streamline QC processes across laboratories, minimizing the need for time-lapse imaging and promoting uniformity in QC practices for both cell and stem cells.

Introduction: The College of American Pathologists (CAP) Biorepository Accreditation Program (BAP) was established in 2012 with the goal of providing standardized requirements that ensure high quality for procuring, processing, storing, distributing, and computerizing information of biospecimens for scientific investigations. CAP BAP was the first biorepository accreditation program, and, since the program started in 2012, the world's second biorepository accreditation standard was issued by the International Organization for Standardization (ISO) as ISO 20387 in 2018. CAP BAP serves as an interface between several programs and draws best practices from renowned organizations. This elective program is based on a peer-inspection model to ensure that the inspectors have proper expertise and to promote educational efforts through information sharing. On-site inspections occur every 2 years, like other CAP Accreditation Programs, with an interim self-inspection in the off year. The program compliance is assessed based on CAP Accreditation Checklists, which are regularly revised. Objective: This article reviews the accomplishments of the first 10 years of the CAP Biorepository Accreditation Program. Results: As of December 2024, 104 biorepositories are CAP BAP accredited, which increased from 53 accredited biorepositories in 2018. Accreditation of 10 additional biorepositories is underway. A total of 88 inspections were completed between January 2017 and December 2022; 16 were initial inspections and 72 were reinspections. Deficiencies, defined as insufficient or lack of evidence of compliance with a checklist item, were mainly related to equipment/instrumentation (24%), quality management (15%), safety (14%), information technology (13%), personnel (13%), specimen handling and quality control (9%), facilities (6%), and regulatory (6%) issues. The proportion of deficiencies between categories was like the first 5 years. Conclusion: The increased number of accredited biorepositories, in both academic and commercial settings, highlights the continued success of the program and its applicability to maintaining high standards for biorepositories.

Introduction: Advancements in biomedical research depend on the quality and availability of biological samples. Despite their sophisticated storage capabilities, biobanks face significant challenges in sample management, with stored specimens often remaining unused and researchers struggling to access the required samples. Objectives: To analyze the challenges in biospecimen access and traceability, evaluate existing solutions, and propose a framework for integrated sample management in global research collaboration. Methods: A scoping review was conducted across PubMed, Scopus, and Web of Science databases, supplemented by grey literature (2004-2024). The analysis included an examination of Biobank Information Management Systems and an evaluation of sample management systems, tracking technologies, and governance frameworks. Results: The analysis revealed fragmented management systems, with at least 38 different biobanking software solutions offering limited interoperability. Proprietary systems and vendor lock-ins create significant barriers to data sharing. Sample tracking shows the evolution from manual to digital systems; however, cross-institutional tracking remains challenging. Reproducibility issues account for significant challenges in research, whereas inefficient resource utilization persists, with 67% of biobanks citing underutilization as a major concern. Conclusions: Addressing biobank sample access and traceability requires a shift from an institution-centric to an ecosystem-wide approach. Its success depends on integrating technological solutions such as Blockchain, the Internet of Things, and artificial intelligence with governance frameworks while ensuring alignment with stakeholder needs. Future developments should focus on implementing integrated traceability systems that support transparent and accountable sample management across the global research ecosystem.

Objectives: To facilitate the regionalization, specialization, and digitization of biobanks, three issues regarding data collection and application must be addressed (1) integration and distribution of data governance, (2) efficiency and efficacy of data governance, and (3) sustainability of data governance. Methods: We collaborated with stakeholders to identify priorities and assess infrastructure needs through the continuous evaluation and analysis of projects. We developed data management solutions, catalogs, and data models to optimize and support data collection, distribution, and application. Furthermore, ontologies were used to facilitate data integration from multiple sources, and Minimum Information About BIobank Data Sharing (MIABIS) was defined as accessible to all patients. To enhance data integrity, we conducted retrospective and prospective follow-up studies. Results: We completed infrastructure upgrades to match technical solutions and research demands. An information management software with six primary functional divisions was developed for data governance. We optimized the database structure and changed the biospecimen accumulation model from biospecimen-based to patient-centered and service-oriented. Subsequently, we specified 85 attributes of MIABIS to describe the biobank contents. A dual-pillar approach was adopted to expand the biobank's data in collaboration with other institutions, and MIABIS served as a bridge for both vertical and horizontal networks. From 2003 to 2021, we collected a total of 156,997 patient biospecimens/data from 20 cancer types, matching 53,113 cases from follow-up surveys. In addition, we supplied more than 40,000 biospecimens/data points for above 300 scientific research projects. Conclusions: An appropriate information platform for a biobank is fundamental to data collection, distribution, and application, particularly in the context of data-intensive research. We implemented a standardized scientific data structure to fulfill the research requirements. The sustainable development of a biobank depends on a scientific, standardized, and service-oriented data governance approach, along with the efficient utilization of emerging technologies.

Aim of the Survey: When it comes to collaboration between academic biobanks and the pharmaceutical/biotechnology industry, the criteria for effective collaborations are still unclear. Researchers in industry and academic biobanks can have different incentives and requirements that the other party is often not familiar with. This survey was conducted in an attempt to increase understanding of these fundamental knowledge gaps that may be obstacles to optimal collaboration between academia and industry. Key Findings from the Survey: There were 53 total respondents. Although this was a global survey, most respondents (n = 29) were from North America, likely reflecting overall investment in research in this region and possibly increased interactions between academia and industry as well. Most respondent academic biobanks collect multiple sample types with most (>90%) collecting both biofluids (including blood) and tissue. Most of the participating academic biobanks were aware that they were not (35%), or only partially (35%), using the full potential of their inventory. One option for increasing utilization rates is by collaborating with industry partners. The main issues when working with industry were perceived to be a combination of challenges including contractual (55%), consent restrictions (45%), timelines (41%), or time pressure (36%). Time taken to put agreements together was also a significant hurdle (54%), together with the industry's administrative requirements (36%). Brief Conclusions from the Survey: To take advantage of opportunities for joint collaboration, it is essential that the parties involved build trust. The first step is to understand the different requirements and needs of the other party and to establish efficient structures for joint cooperation. This survey has highlighted key areas to be addressed as the next steps for strengthening bonds between academic biobanks and industry partners.

Introduction: Rosemary shrub/plant and Sericin have been documented to show antioxdative properties, however their role in improving post thaw semen quality has not been well established. Objectives: The present study was conducted to investigate the effect of Rosemary leaves extract and Sericin protein on post-thaw quality of Pantja buck semen. Methods: In the first experiment, 32 ejaculates were collected from 4 sexually mature Pantja bucks and pooled to form 8 pooled samples. The pooled samples were evaluated for seminal attributes (sperm motility, viability, morphology, plasma membrane integrity, and acrosomal integrity), status of antioxidative enzymes (superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase) and lipid-peroxidation (malondialdehyde) of sperm plasma membrane before dilution. In the second experiment, pooled samples were divided into three equal aliquots as group-C (Control), group-R (Rosemary), and group-S (Sericin). Aliquots of group-C were diluted in glycerolated Egg Yolk Tris (EYT) extender, whereas aliquots of group-R and group-S were additionally supplemented with 4.0% v/v Rosemary leaves extract and 0.25% w/v Sericin, respectively, and again examined for the above parameters at the post-dilution, post-equilibration, and post-thawing stages of semen freezing. Results: Significant differences (p < 0.05) were observed in the values of seminal attributes, level of enzymatic antioxidants, and lipid per-oxidation between group C and R and between group C and S at the post-thaw stage of semen freezing. However Sericin was nonsignificantly better than Rosemary in improving post-thaw semen quality. Conclusion: The results of the present study on limited semen samples in Pantja buck demonstrated that compared to the control group, both Rosemary aqueous extract (4%) and Sericin protein (0.25%) as an additive in TRIS extender, showed better cryoprotective effects resulting in improved post-thaw seminal characteristics.

Nearly one-third of flora, fauna, and funga species on Earth are threatened with extinction. In response, the prevalence of repositories-often called "biobanks" or "genome resource banks"-for storing biological materials from threatened species has become more widespread. This research examined trends for the (1) terminology, (2) taxa representation, (3) global distribution, and (4) operational approach of biobanks versus genome resource banks relating to zoos and wildlife. Our literature search results indicate that although genome resource banking literature began earlier in the 1990s, biobanking has seen a surge in publications with over 3.5× more literature for biobanking since 2020. Genome resource bank articles were highly focused on mammals (68%), while biobanking literature focused more on multi-taxonomic overviews and less-studied taxa. Our search parameters found the largest number of wildlife biobanks in Europe (18) and the lowest number in South America (2), though results are likely impacted by the search being completed in English. Additionally, only 28% (7/25) of global biodiversity hotspots contain a wildlife biobank based on our methodology. While not all wildlife biobanking efforts are published or reported, these findings suggest that (1) "biobank" will likely be the more widely used term in the future, (2) more biobanking research is needed for non-mammalian taxa, (3) there are geographical gaps in wildlife biobanks, and (4) conservation biobanking programs should focus on storing biospecimens from a wide set of individuals and develop assisted reproductive technologies concomitantly with the goal of maintaining healthy, sustainable populations in the long term.

Introduction: Sperm cryopreservation is a useful storage technique in artificial insemination. Nanoparticles and nanovesicles such as exosomes are widely used in sperm cryopreservation procedures to alleviate cold-induced injury inflicted during sperm freezing. Objective: The objective of the present study was to examine the impact of varying concentrations of exosomes derived from seminal plasma added to a freezing extender on the quality of post-thawed bull sperm. Methods: Five Holstein bulls were chosen based on their samples having less than 30% progressive motility. After exosome extraction, semen samples from bulls (n = 5) with progressive sperm motility ≤30% were collected, diluted with different exosome concentrations (0, 25, 50, and 100 μg/mL), and aspirated into 0.5 mL straws. After the freeze-thaw process, sperm total and progressive motility, viability, morphology, plasma membrane integrity, mitochondrial activity, and apoptosis status were assessed. Furthermore, the expression levels of annexin (ANX1), dystrophy-associated Fer-1-like protein (DYSF), fibronectin 1 (FN1), and reactive oxygen species modulator 1 (ROMO1) were evaluated via real-time polymerase chain reaction (PCR). Results: Adding different concentrations of exosomes (25, 50, and 150 μg/mL) significantly increased the progressive motility, viability, and membrane integrity of sperm compared with the control group (p < 0.05). For the apoptosis index, treatment with 100 μg/mL exosomes significantly increased the percentage of live cells (p < 0.05), while the percentage of necrotic cells decreased significantly (p < 0.05) compared with 25 μg/mL exosome. The results of quantitative PCR showed that the expression levels of ANX1 were significantly (p < 0.05) upregulated at 50 μg/mL exosome, and the expression of ROMO1, FN1, and DYSF were downregulated upon treatment with different exosome concentrations. Conclusions: In conclusion, supplementing the freezing diluent with exosome-derived seminal plasma could preserve the quality parameters of the post-thaw semen of the bull with low freezeability and could be used as a helpful method for reproductive programs.

Adequate hypothermic storage of human mesenchymal stem cells (hMSCs) is of fundamental importance since they have been explored in several regenerative medicine initiatives. However, the actual clinical application of hMSCs necessitates hypothermic storage for long periods, a process that requires the use of non-toxic and efficient cryo-reagents capable of maintaining high viability and differentiating properties after thawing. Current cryopreservation methods are based on cryoprotectant agents (CPAs) containing dimethylsulphoxide (DMSO), which have been shown to be toxic for clinical applications. In this study, we describe a simple and effective trehalose (TRE)-based solution to cryo-store human umbilical cord-derived MSCs (UC-MSCs) in liquid nitrogen. Cells viability, identity, chromosomal stability, proliferative and migration capacity, and stress response were assessed after cryopreservation in TRE as CPA, testing different concentrations by itself or in combination with ethylene glycol (EG). Here we show that TRE-stored UC-MSCs provided lower cell recovery rates compared with DMSO-based solution, but maintained good functional properties, stability, and differentiating potential. The best cell recovery was obtained using 0.5 M TRE with 10% EG showing no differences in the osteogenic, adipogenic, and chondrogenic differentiation capacity. A second cycle of cryopreservation in this TRE-based solution had no additional impact on the viability and morphology, although slightly affected cell migration. Furthermore, the expression of the stress-related genes, HSPA1A, SOD2, TP53, BCL-2, and BAX, did not show a higher response in UC-MSCs cryopreserved in 0.5 M TRE + 10% EG compared with DMSO. Together these results, in addition to ascertained therapeutic properties of TRE, provide sufficient evidence to consider TRE-based medium as a low-cost and efficient solution for the storage of human UC-MSCs cells and potentially substitute DMSO-based cryo-reagents.